Using tumor analytics to improve cancer treatment with immunotherapy and targeted inhibitors
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
['FUNDING_OTHER'] · INSTITUTE FOR SYSTEMS BIOLOGY · NIH-11131308
This study is looking at a new way to treat cancer by using two types of therapies—targeted inhibitors and immunotherapy—in a specific order to see if it works better, especially for people with melanoma and brain metastases, so that patients can have more effective treatment options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INSTITUTE FOR SYSTEMS BIOLOGY (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11131308 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new approach to cancer treatment by combining targeted inhibitors with immunotherapy in a sequential manner rather than simultaneously. By analyzing past clinical data and using advanced therapeutic models, the researchers aim to understand how this sequence can enhance treatment effectiveness, particularly in cases of melanoma and brain metastases. The study will explore various factors such as dosing, timing, and treatment order to optimize patient outcomes. Patients may benefit from more effective treatment strategies that could reduce resistance to therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma or other cancers who are considering immunotherapy or targeted inhibitor treatments.
Not a fit: Patients with cancers that do not respond to immunotherapy or targeted inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient survival and quality of life.
How similar studies have performed: Previous research has shown promising results with sequential treatment approaches in cancer therapy, indicating potential for success in this novel approach.
Where this research is happening
SEATTLE, UNITED STATES
- INSTITUTE FOR SYSTEMS BIOLOGY — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HEATH, JAMES R. — INSTITUTE FOR SYSTEMS BIOLOGY
- Study coordinator: HEATH, JAMES R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers